Items Tagged ‘Votrient’

March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer


The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the […]

View full entry

Tags: Bladder Cancer, News, paclitaxel, pazopanib, Phase II study, Recurrent Bladder Cancer, Stages II-III Bladder Cancer, Taxol, Votrient